TX-MARY-KAY
Mary Kay Inc., a global beauty company and leader in skin care innovation, continues its ongoing support of the beauty and scientific communities by participating in two major global conferences in Europe this month: the 24th World Congress of Dermatology (WCD), June 10–15 in Milan, Italy and the 5th Future of Formulations in Cosmetics Summit, June 19-20, in Dusseldorf, Germany.
Held every four years, the World Congress of Dermatology is the largest dermatology meeting in the world. The WCD’s 2019 theme, “A New Era for Global Dermatology,” was the perfect match for Mary Kay to present its applied science findings and continue the scientific conversation around pollution and skin damage. On June 12, Mary Kay will host a symposium at the event titled “Environmental Stressors and Skin: Beyond UV.”
The symposium will explore the impact of external environmental aggressors on skin health, with a focus on Europe and how antioxidants can help reduce the damaging effects of pollution. Moderated by Michelle Hines, Ph.D., Director, Global Upstream Research & Technology at Mary Kay, the symposium will feature two renowned European skin experts:
- Jean Krutmann , M.D., Professor & Director at Leibniz Research Institute for Environmental Medicine – Dusseldorf, Germany.
- Stefanie Williams, M.D., Dermatologist & Medical Director at EUDELO – London, United Kingdom.
The extent of air pollution’s impact on skin and overall health was recently revealed in a new comprehensive global review by the Forum of International Respiratory Societies’ Environmental Committee, that reported air pollution may potentially affect every organ in the human body.* The report is especially relevant to the European region, as many European cities have been found to exceed air pollution limits set by the World Health Organization (WHO) or the European Environment Agency (EEA).
In fact, more than 40 towns and cities in the UK alone exceed WHO air pollution limits** and the EEA named 15 cities that are worst affected by dust particle, nitrogen dioxide and sulfur dioxide pollution*** in Germany. Excessive levels of pollution have adverse impact on overall health and are also detrimental to skin health, texture and appearance.
A pioneer of environmental medicine, Professor Krutmann has been relentlessly working in the field of skin protection. “Since I discovered in 2010 that air pollution causes skin aging and skin pigmentation, my institute has conducted a lot of research to verify this observation and to unravel the underlying mechanisms. From these studies it is now clear that long term exposure to traffic-related particulate matter (PM) is not only dangerous for our lungs and cardiovascular system, but skin health is compromised as well,” stated Jean Krutmann, M.D.
Stefanie Williams, M.D., further explained: “We might not be able to separate the damage caused to the skin by UV exposure from those caused by air pollution clinically; however, given the major research advances made in skin and air pollution science, my expectation is that the adverse effects of pollution on skin health will continue to have a growing impact in the future in high-density cities," explained Dr. Williams.
During Mary Kay’s presentation at the 5th Future of Formulations in Cosmetics Summit, Michelle Hines, Ph. D. will reveal Mary Kay’s latest research on an antioxidant complex that helps delay the onset of premature signs of skin aging related to the damaging effects of diesel exhaust particles (DEP). The breakthrough technology, found in the Mary Kay® TimeWise® Miracle Set 3D™ skin care line, provides a powerful free-radical fighting regimen with an exclusive, patent-pending, three-dimensional approach to skin aging.
“Experts have confirmed the significant negative impact of air pollution on skin and this impact will continue to grow as environmental stressors, such as DEP, and pollution levels increase, especially in densely populated urban areas,” Dr. Hines noted. “Mary Kay has discovered targeted technologies that help delay the onset of premature skin aging from unavoidable environmental and lifestyle stressors. Simultaneously, Mary Kay has been advancing scientific discussions with renowned experts around the globe to drive awareness on the negative impact of pollution on skin.”
As one of the world’s leading cosmetics and skincare industry innovators, Mary Kay’s participation in the 24th World Congress of Dermatology and the 5th Future of Formulations in Cosmetics Summit, are the latest installments in a series of global partnerships with the scientific and academic international communities.
Further demonstrating its long-lasting commitment to funding and contributing to skin health research, Mary Kay has also presented research on the topic of skin and pollution in North America at the International Investigative Dermatology meeting in May 2018, in Orlando, Florida, and in Latin America at the Reunion Anual de Dermatologos Latinoamericanos , in May 2019, in Buenos Aires, Argentina.
Every year, Mary Kay invests millions of dollars in research and development, and conducts hundreds of thousands of scientific tests on products and ingredients to ensure the highest standards of safety, quality and performance. Mary Kay holds more than 1,500 patents for products, technologies and packaging designs in its global portfolio.
*Review by the Forum of International Respiratory Societies’
Environmental Committee, Part 1: The Damaging Effects of Air Pollution
(February 2019)
** WHO Global Ambient Air Quality Database
(update 2018)
***Report by
Bundesministerium für Umwelt, Naturschutz, Bau und Reaktorsicherheit,
Berlin, Germany. 2015 (Translation: Federal Ministry for Environment,
Nature Conservation, and Nuclear Safety).
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 55 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics and nutritional supplements. Through the Mary Kay Foundation™, the company has awarded more than $78 million to cancer research and causes to help end domestic violence. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at www.marykay.com
About the WCD Meeting
The World Congress of Dermatology (WCD) - is the largest Dermatology meeting in the world. It is held every four years on various continents. The 24th WCD was held in Milano and hosted by the Italian Society of Dermatology (SIDeMaST) from June 10-15, 2019 under the auspices of the International League of Dermatological Societies. It has been over 40 years since Milan last hosted the WCD. The Meeting focused on major breakthroughs and advances in Dermatology, ranging from clinical practice to research, technology and innovation. Learn more at www.wcd2019milan.org
About the 5th Future of Formulations in Cosmetics Summit
The 5th Future of Formulations in Cosmetics Summit brings together senior executives and experts from raw materials and active ingredients manufacturers, chemical companies, major associations, technology companies, brand owners, cosmetic companies, testing companies to discuss the latest changes, challenges and developments within the industry. The 5th Future of Formulations in Cosmetics Summit will be held in Dusseldorf in Germany on June 19-20, 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190609005044/en/
Contact:
Mary Kay Inc. Corporate Communications marykay.com/newsroom 972.687.5332 or media@mkcorp.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Overture Life Launches European Preorder Waitlist for DaVitri, the World’s First Microfluidics-Based Automated Vitrification Platform17.9.2025 07:00:00 CEST | Press release
Ahead of receipt of anticipated CE Mark, European customers can begin requesting DaVitri to expand patient access to high-quality IVF Overture Life, the innovator modernizing IVF to optimize reproductive freedom, today announced the launch of its European preorder waitlist for DaVitri, the world’s first automated vitrification platform. The waitlist ensures in vitro fertilization (IVF) facilities will be among the first in Europe to harness DaVitri to reduce manual workloads for their embryologists while eliminating operator variability, thereby providing patients with faster, more consistent procedures. As infertility rates spike worldwide, interest in egg freezing continues to rise while the infrastructure to support it lags behind. Egg freezing requires vitrification, typically a time-intensive, manual process vulnerable to human error that can only be performed by extensively trained embryologists. This has resulted in variability in egg and embryo survival rates that directly impa
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 202517.9.2025 07:00:00 CEST | Press release
Across both STOP-HS1 and STOP-HS2, povorcitinib treatment resulted in continued clinically meaningful and statistically significant improvements for patients with active moderate to severe hidradenitis suppurativa (HS) through Week 24At Week 24, nearly 60% of efficacy-evaluable patients among both povorcitinib treatment groups achieved HiSCR50Additionally, patients treated with povorcitinib achieved HiSCR75 (31.0%-40.3%), HiSCR90 (13.8%-27.7%) and HiSCR100 (9.2%-21.3%) through Week 24Povorcitinib-treated patients also achieved greater improvements in skin pain by the first visit (Week 3) through Week 24 with 62%-70% achieving mild or no pain at Week 24 Incyte (Nasdaq:INCY) today announced new 24-week interim data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). These data will
Galderma’s Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin17.9.2025 07:00:00 CEST | Press release
Results from a real-world clinical study conducted in China, to be presented at the European Academy of Dermatology and Venereology (EADV) 2025 Congress, reveal that modern lifestyles and environmental triggers significantly impact individuals with sensitive skin1 Data show that people with sensitive skin living in modern environments have higher levels of inflammation compared to those living traditional, less stressful lifestyles1 This first-of-its-kind study was conducted by Galderma’s Global Sensitive Skincare Faculty (GSSF) as part of the company’s commitment to transforming the understanding and care of sensitive skin1 Galderma today announced new data from a first-of-its-kind real-world clinical study conducted in China assessing the biological impact of different lifestyles and their associated environmental factors on individuals with sensitive skin.1 Results from the study, conducted by dermatology experts from Galderma’s Global Sensitive Skincare Faculty (GSSF), will be pres
Ant International Recognized as an Inaugural Foreign Institution Partner by China’s Cross-Border Interconnection Payment Gateway17.9.2025 06:24:00 CEST | Press release
Expanded direct connection enables Alipay+ to help global wallets build China merchant networkAnt is the largest player in the CPG scheme in terms of coverage, use cases and business volume Ant International is appointed as an inaugural foreign Institution Partner (FIP) of China’s Cross-border Interconnection Payment Gateway (CPG), under the guidance of the People’s Bank of China and the Payment & Clearing Association of China (PCAC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916704996/en/ Eric Jing, Chairman of Ant Group and Ant International, and Cyril Han, CEO of Ant Group, celebrating China's Top International consumer destinations with card and wallet partners. Ant International and Alipay are the largest player in the CPG scheme with the largest number of card network and wallet partners, the broadest use cases and largest business volume. The new CPG scheme is designed to raise connection efficiency and improv
Ant International Joins Google's Agent Payments Protocol as a Launch Partner17.9.2025 06:00:00 CEST | Press release
Co-building a trusted foundation for agentic commerce Ant International, a leading global provider of digital payments, digitisation, and financial technology, today announced its role as a launch partner of Google to develop Agent Payments Protocol (AP2), an open rulebook that defines how AI agents can reliably transact with the authorisation of users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916339888/en/ With the rise of agentic commerce, AI agents will increasingly transact on behalf of users for services, products, and even other agents. Existing payment systems are built around direct human interaction and cannot currently address the new requirements of authorization, verification, and interoperability among agents. To address this gap, Google has collaborated with the industry to introduce AP2. AP2 defines the key components of agentic payments and provides a protocol to ensure user intent is verifiable, tra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom